At the Inserm VirPath laboratory, is covid-19 analyzed, dissected and manipulated in order to find an effective treatment?
–
Researchers in Lyon, from Inserm, CNRS, Université Claude Bernard Lyon 1 and ENS Lyon, announce that the association between the remdesivir molecule, used in the treatment of Ebola, and the antihypertensive agent diltiazem could provide “significant benefit” in patients with covid-19. Promising.
This is THE big current research. How to best treat covid-19? With what treatment? Researchers around the world are multiplying.
In Lyon, the Virpath team led by Inserm researcher Manuel Rosa-Calatrava at the International Center for Infectious Disease Research (Inserm / CNRS / Université Claude Bernard Lyon 1 / ENS Lyon) announces that the association between the remdesivir molecule, used in the treatment of Ebola, and the antihypertensive drug diltiazem could provide “a significant benefit“in patients with covid-19.
“To test the therapeutic efficacy of these molecules against Covid-19, the team developed and characterized experimental models of viral infections as early as February. For this, she reconstituted in vitro, as close as possible to human physiology, human respiratory epithelia of nasal and bronchial origin.“, explains Inserm.
A clinical trial starting next winter?
“By stimulating the innate immune response of the epithelia [tissus] respiratory, diltiazem potentiates the effect of remdesivir and offers the opportunity to reduce the doses. Remdesivir indeed has a certain toxicity in vivo in addition to being a very expensive drug.“, emphasizes Manuel Rosa-Calatrava.
“The team is continuing its preclinical trials with this dual therapy in animal models and hopes to launch a clinical trial next winter if the positive results are confirmed.“, continues Inserm. Promising.
More information here.
–
